Trials / Terminated
TerminatedNCT01963715
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMGN289 |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2013-10-16
- Last updated
- 2015-10-02
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01963715. Inclusion in this directory is not an endorsement.